Jefferies downgraded Point Biopharma (PNT) to Hold from Buy with a $12.50 price target after Eli Lilly (LLY) announced an agreement to acquire Point for $12.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PNT:
- Point Biopharma downgraded to Hold from Buy at Truist
- H.C. Wainwright sees Actinium Pharmaceuticals as prime candidate for acquisition
- Eli Lilly deal for Point puts radiopharma names in spotlight
- JMP Securities remains bullish on Lantheus after Lilly’s acquisition of Point Biopharma
- Point Biopharma deal reads positively to radiopharma names, says B. Riley